Excellent quality Sevoflurane - Ibutamoren mesylate 214962-40-0 Hormone and endocrine – Neore
Excellent quality Sevoflurane - Ibutamoren mesylate 214962-40-0 Hormone and endocrine – Neore Detail:
Payment: T/T, L/C
Product Origin: China
Shipping Port: Beijing/Shanghai/Hangzhou
Production capacity: 60kg/month
Order(MOQ): 25kg
Lead Time: 3 Working Days
Storage condition: Stored in cool and dry place, sealed and keep away from light.
Package material:drum
Package size:25kg/drum
Safety information: Not dangerous goods
Introduction
Ibutamoren mesylate, also named MK677, is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been shown to increase the secretion of several hormones including GH and insulin-like growth factor 1 (IGF-1) and produces sustained increases in the plasma levels of these hormones without affecting cortisol levels.
Specification (in house standard)
|
Item |
Specification |
| Appearance | White to off-white powder |
| 1HNMR | Conforms to structure |
| LC-MS | [M-Methanesulfonicacid+H]+：(530.1-530.2) |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metal | <10ppm |
| Purity by HPLC | ≥99.0% |
Product detail pictures:
Related Product Guide:
We have been experienced manufacturer. Wining the majority of the crucial certifications of its market for Excellent quality Sevoflurane - Ibutamoren mesylate 214962-40-0 Hormone and endocrine – Neore , The product will supply to all over the world, such as: Durban, Romania, Southampton, We rely on high-quality materials, perfect design, excellent customer service and the competitive price to win the trust of many customers at home and abroad. 95%products are exported to overseas markets.
By Janet from New York - 2017.12.02 14:11
We have worked with many companies, but this time is the best，detailed explanation, timely delivery and quality qualified, nice!
By Agatha from Zurich - 2018.02.21 12:14
